

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-11. Cancelled.

12. (previously presented) A method of treatment of a human patient for cancer, comprising administering Et 743 in cycles by intravenous infusion at intervals of about 1-6 weeks with an infusion time of about 2 to about 24 hours.

13. (previously presented) A method according to claim 12, wherein the Et 743 is administered with an infusion time of about 3 hours.

14. (previously presented) A method according to claim 12, wherein the Et 743 is administered with an infusion time of about 24 hours.

15. (previously presented) A method according to claim 12, wherein the Et 743 is administered at intervals of about 1 week.

16. (previously presented) A method according to claim 12, wherein the patient is allowed to recover for the remainder of the cycle.

17. (previously presented) A method according to claim 12, wherein the cycle is 3 or 4 weeks.

18. (previously presented) A method according to claim 12, wherein the cancer is melanoma, leiomyosarcoma, colon stromal sarcoma, gastric stromal sarcoma, osteosarcoma, liposarcoma, breast cancer, ovarian cancer, mesothelioma, or ocular melanoma.

19. (previously presented) A method according to claim 12, wherein the cancer has metastasized.

20. (previously presented) A method according to claim 12, wherein the patient has been previously treated for cancer with chemotherapy.

21. (previously presented) A method according to claim 12, further comprising the administration of at least one additional drug.

22. (previously presented) A method according to claim 21, wherein the at least one additional drug is selected from: a) a drug with an antimitotic effect; b) an antimetabolite drug; c) an alkylating agent or nitrogen mustard; d) a drug which targets DNA; e) a drug which targets topoisomerase; f) a hormone or a hormone agonist or antagonist; g) a drug which targets signal transduction in tumor cells; h) an alkylating drug; i) a drug potentially affecting metastasis of tumors; j) a gene therapy or antisense agent; k) an antibody therapeutic; l) a bioactive compound of marine origin; m) a steroid analog; n) an anti-inflammatory drug; or o) an anti-emetic drug.